Treating sexual dysfunction
The present disclosure describes use of oxytocin, in combination with one or more other agents as described herein, for use for example in the treatment of certain conditions.
1. A method comprising administering to a subject suffering from sexual dysfunction intranasal oxytocin, wherein the subject has received or is receiving at least one sublingual 5-HT1A partial agonist, so that the subject receives combination therapy with both.
2. The method of claim 1 , wherein the step of administering comprises administering both the intranasal oxytocin and the sublingual 5-HT1A partial agonist to the subject.
3. The method of claim 1 , wherein the sexual dysfunction is (i) delayed orgasm and/or (ii) difficulty achieving orgasm and is secondary to current and/or prior use of psychotropic medications.
4. The method of claim 1 , wherein the subject is a woman.
5. The method of claim 4 , wherein the subject is a post-menopausal woman.
6. The method of claim 1 , wherein the subject does not adequately respond to available medications or is unable to tolerate available medications because of side effects and/or contraindications.
7. The method of claim 1 , wherein the subject is a male.
8. The method of claim 1 , wherein the step of administering the intranasal oxytocin occurs approximately 5 minutes to six hours prior to sexual activity.
9. The method of claim 8 , wherein the step of administering the intranasal oxytocin occurs approximately 30 minutes to 120 minutes, 30 minutes to 60 minutes, or 5 minutes to 20 minutes prior to sexual activity.
10. The method of claim 1 , further comprising administration of at least one additional agent that (i) modulates one or more of parasympathetic activity, sympathetic activity, or oxytocin secretion and/or (ii) can act as a contextual modifier to augment biological activity of oxytocin.
11. The method of claim 1 , wherein the intranasal oxytocin is administered prior to the at least one sublingual 5-HT1A partial agonist.
12. The method of claim 10 , wherein the at least one additional agent is administered prior to, subsequent to, or concomitant with (i) the intranasal oxytocin; and/or (ii) the at least one sublingual 5-HT1A partial agonist.
13. A method comprising administering to a subject suffering from sexual dysfunction at least one sublingual 5-HT1A partial agonist, wherein the subject has received or is receiving intranasal oxytocin, so that the subject receives combination therapy with both.
14. The method of claim 13 , wherein the step of administering comprises administering both the at least one sublingual 5-HT1A partial agonist and the intranasal oxytocin to the subject.
15. The method of claim 13 , wherein the sexual dysfunction is (i) delayed orgasm and/or (ii) difficulty achieving orgasm and is secondary to current and/or prior use of psychotropic medications.
16. The method of claim 13 , wherein the subject is a woman.
17. The method of claim 13 , wherein the subject is a post-menopausal woman.
18. The method of claim 13 , wherein the subject does not adequately respond to available medications or is unable to tolerate available medications because of side effects and/or contraindications.
19. The method of claim 13 , wherein the subject is a male.
20. The method of claim 13 , wherein the step of administering the at least one sublingual 5-HT1A partial agonist occurs approximately 5 minutes to six hours prior to sexual activity.
21. The method of claim 20 , wherein the step of administering the at least one sublingual 5-HT1A partial agonist occurs approximately 30 minutes to 120 minutes, 30 minutes to 60 minutes, or 5 minutes to 20 minutes prior to sexual activity.
22. The method of claim 13 , further comprising administration of at least one additional agent that (i) modulates one or more of parasympathetic activity, sympathetic activity, or oxytocin secretion and/or (ii) can act as a contextual modifier to augment biological activity of oxytocin.
23. The method of claim 13 , wherein the at least one sublingual 5-HT1A partial agonist is administered concomitant with the intranasal oxytocin.
24. The method of claim 13 , wherein the at least one sublingual 5-HT1A partial agonist is administered prior to the intranasal oxytocin.
25. The method of claim 22 , wherein the at least one additional agent is administered prior to, subsequent to, or concomitant with (i) the at least one sublingual 5-HT1A partial agonist and/or (ii) the intranasal oxytocin.